Soluble β-amyloid (Aβ) 40 causes attenuation or potentiation of noradrenaline-induced vasoconstriction in rats depending upon the concentration employed

Neuroscience Letters

Volumn 367, Issue 1, 2004, Pages 129-132

  Smith, Christopher C T ^a   Stanyer, Lee ^a   Betteridge, D John ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Amyloid; Alzheimer's disease; Noradrenaline; Vasoactivity

Indexed keywords

AMYLOID BETA PROTEIN; NITRIC OXIDE; NORADRENALIN; PROSTACYCLIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RAT STRAIN; VASCULAR RING; VASOCONSTRICTION; VASODILATATION;

AMYLOID BETA-PROTEIN; ANIMALS; AORTA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; NOREPINEPHRINE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; VASOCONSTRICTION;

EID: 4043067902     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.05.094     Document Type: Article

References (14)

1. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:2002;507-511
2. Chen M., Inestrosa N.C., Ross G.S., Fernandez H.L. Platelets are the primary source of amyloid β-peptide in human blood. Biochem. Biophys. Res. Commun. 213:1995;96-103
3. Crawford F., Soto C., Suo Z., Fang C., Parker T., Sawar A., Frangione B., Mullan M. Alzheimer's β-amyloid vasoactivity: identification of a novel β-amyloid conformational intermediate. FEBS Lett. 436:1998;445-448
4. Crawford F., Suo Z., Fang C., Mullan M. Characteristics of the in vitro vasoactivity of β-amyloid peptides. Exp. Neurol. 150:1998;159-168
5. Hardy J., Alsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12:1991;383-388
6. Li Q-X., Whyte S., Tanner J.E., Evin G., Beyreuther K., Masters C.L. Secretion of Alzheimer's disease Aβ amyloid peptide by activated human platelets. Lab. Inv. 78:1998;461-469
7. May P.C., Gitter B.D., Waters D.C., Simmons L.K., Becker G.W., Small J.S., Robison P.M. β-Amyloid peptide in vitro toxicity: lot to lot variability. Neurobiol. Aging. 13:1992;605-607
8. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870
9. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., McCormack R., Wolfert R., Selkoe D., Lieberburg I., Schenk D. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 359:1992;325-327
10. Smith C.C.T. Stimulated release of the β-amyloid protein of Alzheimer's disease by normal human platelets. Neurosci. Lett. 235:1997;157-159
11. Smith C.C.T., Hyatt P.J., Stanyer L., Betteridge D.J. Platelet secretion of β-amyloid is increased in hypercholesterolaemia. Brain Res. 896:2001;161-164
12. Stanyer L., Betteridge D.J., Smith C.C.T. An investigation into the mechanisms mediating plasma lipoprotein-potentiated β-amyloid fibrillogenesis. FEBS Lett. 518:2002;72-78
13. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. β-amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 380:1996;168-171
14. Walsh D.M., Klyubin I., Fadeeva J., Cullen W.K., Anwyl R., S Wolfe M., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539